NICE technology appraisal guidance TA875 supports the use of semaglutide 2.4 mg (Wegovy) for adults who meet specific criteria: BMI 35 kg/m with at least one weight-related comorbidity (such as type 2 diabetes, hypertension, or obstructive sleep apnoea) BMI 3034.9 kg/m in certain higher-risk groups For people from certain ethnic backgrounds including South Asian, Chinese, other Asian, Middle Eastern, Black African, and African-Caribbean groups lower BMI thresholds apply (typically approximately 2.5 kg/m lower than standard thresholds), in line with NHS and NICE guidance on ethnicity-related metabolic risk Treatment must be delivered as part of a specialist weight management service providing multidisciplinary support Treatment duration under TA875 is limited to a maximum of 2 years Should retatrutide receive regulatory approval and a positive NICE appraisal, it is likely that similar eligibility criteria would apply, potentially with additional considerations given its more potent mechanism of action
What you'll learn What are GLP-1 medications
Schulz C, Kammerer S, Kpper JH
Peptides for skin research include copper peptides (GHK-Cu, AHK-Cu), melanocortin peptides (Melanotan 1 & 2), and synthetic peptides like Snap-8 studied for facial muscle research
Another study reported in December 2025, suggested GLP-1 drugs may be involved in a rare subtype of a hereditary tumor called neuroendocrine neoplasm
Tylenol + the wrong genes = a bad combination
